Please assess the completion status of the following clinical trial:

Trial Title: A Study of Baricitinib (LY3009104) in Adults With Severe or Very Severe Alopecia Areata

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Are at least 18 years and ≤60 years for males (≤70 years of age for females) at the time of informed consent.~* Have severe or very severe AA, as determined by all of the following:~  * Current AA episode of more than 6 months' duration and hair loss encompassing ≥50% of the scalp, as measured by SALT (AA-IGA of 3 or 4) at screening and baseline.~ * No spontaneous improvement over the past 6 months.~ * Current episode of severe or very severe AA of less than 8 years. Note: participants who have severe or very severe AA for ≥8 years may be enrolled if episodes of regrowth, spontaneous or under treatment, have been observed on the affected areas over the past 8 years.~* Male or nonpregnant, nonbreastfeeding female participants.~Exclusion Criteria:~* Primarily diffuse type of AA.~* Are currently experiencing other forms of alopecia or any other concomitant conditions that would interfere with evaluations of the effect of study medication on AA.~* Previously treated with an oral Janus kinase (JAK) inhibitor and had an inadequate response (for example, absence of significant terminal hair growth after at least 12 weeks of treatment).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- 4 Milligram (mg) Baricitinib (Type: EXPERIMENTAL): Participants received one 4 mg Baricitinib tablet administered orally, every day (QD) one placebo tablet administered orally QD to maintain blind.
- 2 mg Baricitinib (Type: EXPERIMENTAL): Participants received one 2 mg Baricitinib tablet administered orally QD, and one placebo tablet administered orally QD to maintain blind.
- Placebo (Type: PLACEBO_COMPARATOR): Participants received two placebo tablets administered orally QD to maintain the blind.
- 4 mg Baricitinib Maximum Extended Enrollment (MEE) (Type: EXPERIMENTAL): Participants received one 4 mg Baricitinib tablet administered orally, every day (QD) one placebo tablet administered orally QD to maintain blind.
- 2 mg Baricitinib MEE (Type: EXPERIMENTAL): Participants received one 2 mg Baricitinib tablet administered orally QD, and one placebo tablet administered orally QD to maintain blind.
- Placebo MEE (Type: PLACEBO_COMPARATOR): Participants received two placebo tablets administered orally QD to maintain the blind.

Based on this trial design, predict the completion outcome and termination type (if applicable).